Leadership Overview
Indivior has 4 executives leading key functions including corporate experience, executive administration, information technology, and legal affairs.
Committed to transforming addiction treatment, Indivior advances science-driven therapies for opioid and alcohol use disorders. This organization prioritizes patient-centered care to improve global health outcomes through innovative pharmaceutical solutions.
Committed to transforming addiction treatment, Indivior advances science-driven therapies for opioid and alcohol use disorders. This organization prioritizes patient-centered care to improve global health outcomes through innovative pharmaceutical solutions.
Leadership Roles at Indivior
Tonia Parker - Head of Indivior Experience and Office of the Chief Executive Officer
Tonia Parker, the Head of Indivior Experience and Office of the Chief Executive Officer at Indivior, manages internal organizational culture and executive operations. Parker coordinates strategic initiatives across the enterprise to ensure alignment with the mission of treating addiction as a chronic disease. By streamlining communication between the executive leadership and internal departments, the Head of Indivior Experience and Office of the Chief Executive Officer fosters a cohesive environment conducive to pharmaceutical innovation. Tonia Parker also monitors the efficacy of internal programs designed to support patient-centered care initiatives. Through the oversight of cross-functional projects, the Head of Indivior Experience and Office of the Chief Executive Officer drives operational excellence across global teams. This leadership role requires constant collaboration with senior management to refine corporate processes. Ultimately, Parker strengthens the organizational framework necessary for delivering evidence-based treatments to patients worldwide.
Cynthia Cuccia - Executive Administrator & President & Chief Executive Officer & Chief Financial Officer
Cynthia Cuccia, the Executive Administrator & President & Chief Executive Officer & Chief Financial Officer at Indivior, directs the overarching financial strategy and corporate governance of the pharmaceutical firm. Cuccia oversees the allocation of capital toward research and development of therapies for opioid and alcohol use disorders. As the Executive Administrator & President & Chief Executive Officer & Chief Financial Officer, Cynthia Cuccia maintains fiscal discipline while expanding market access for evidence-based treatments. This role involves high-level engagement with the Board to ensure long-term sustainability and growth across international markets. By balancing financial performance with the core mission of improving patient outcomes, the Executive Administrator & President & Chief Executive Officer & Chief Financial Officer secures the resources required for manufacturing innovative medicines. Cuccia leads the executive team in executing the global vision, ensuring that every strategic decision supports the commitment to addressing serious mental illnesses through science-driven solutions.

Jon Redick - Chief Information Officer & Chief Innovation Officer
Jon Redick, the Chief Information Officer & Chief Innovation Officer at Indivior, architects the digital infrastructure and technological roadmap for the company. Redick integrates advanced data analytics into the research and development process to accelerate the creation of therapies for addiction. As the Chief Information Officer & Chief Innovation Officer, Jon Redick oversees the implementation of secure systems that protect sensitive patient data while facilitating global collaboration. This leadership role focuses on leveraging emerging technologies to optimize manufacturing processes and supply chain efficiency. By driving digital transformation, the Chief Information Officer & Chief Innovation Officer ensures that the organization remains at the forefront of pharmaceutical innovation. Redick collaborates with other C-suite leaders to align technological investments with the broader goal of expanding access to evidence-based treatment. Through these efforts, the Chief Information Officer & Chief Innovation Officer enhances the operational capacity required to deliver life-changing medicines to patients across diverse geographic regions.

Jeff Burris - Chief Legal Officer
Jeff Burris, the Chief Legal Officer at Indivior, directs all regulatory compliance and legal strategy for the global pharmaceutical operations. Burris manages complex intellectual property portfolios and ensures adherence to international standards for the development and commercialization of addiction treatments. As the Chief Legal Officer, Jeff Burris provides critical guidance on risk management and corporate governance to the executive team. This role involves navigating the intricate legal landscape of the pharmaceutical industry to protect the company's innovative therapies. By overseeing legal affairs, the Chief Legal Officer supports the expansion of evidence-based treatment access across multiple countries. Burris works closely with the Board to address regulatory challenges and maintain the highest standards of ethical conduct. Through proactive legal oversight, the Chief Legal Officer safeguards the organization's ability to focus on patient-centered care. Ultimately, Burris ensures that all business activities align with legal requirements while advancing the mission of treating serious mental illnesses.
Explore Leadership Teams in Manufacturing
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The company invests heavily in research and development, maintaining a robust pipeline of innovative medicines and diagnostic solutions while collaborating with academic institutions, biotechnology companies, and healthcare partners worldwide. Headquartered in Basel, Switzerland, Roche operates globally with a presence in numerous countries, employing a diverse workforce of scientists, researchers, healthcare professionals, and business experts dedicated to transforming patient care and making a meaningful difference in the fight against serious diseases.
Company Leadership CB

JC
Merz North America Inc is a company that operates in the Pharmaceuticals industry. It employs 1000to4999 people and has 500Mto1G of revenue. The company is headquartered in Raleigh, North Carolina.
Company Leadership

AR
PU
Biogen is a U.S.-based biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological and neurodegenerative diseases. Its core portfolio includes treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and other rare neurological disorders, supported by advanced research in neuroscience, biologics, and gene-based therapies.
Company Leadership

ER

Dexcel Pharma is Israel’s largest privately owned pharmaceutical company, founded in 1968 and headquartered in Or Akiva. It develops, manufactures, and commercializes value‑added branded prescription drugs, generics, and OTC products—primarily oral solid dosage forms—supplying more than 85 products in over 175 dosage forms to markets including the U.S., U.K., Germany, Austria, and others through subsidiaries and distribution partners.
Company Leadership DO
IO

ZT